Despite the potentially beneficial effects of mTOR inhibitors on HCC recurrence following liver transplantation, there are currently only retrospective and uncontrolled clinical trials available from which to draw supportive evidence [17]. This evidence concerns the gene MTOR and hepatocellular carcinoma.